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Abstract
Background: Fascin-1 is an actin crosslinking protein that is important for the assembly of cell protrusions in
neurons, skeletal and smooth muscle, fibroblasts, and dendritic cells. Although absent from most normal adult
epithelia, fascin-1 is upregulated in many human carcinomas, and is associated with poor prognosis because of its
promotion of carcinoma cell migration, invasion, and metastasis. Rac and Cdc42 small guanine triphosphatases
have been identified as upstream regulators of the association of fascin-1 with actin, but the possible role of Rho
has remained obscure. Additionally, experiments have been hampered by the inability to measure the fascin-1/
actin interaction directly in intact cells. We investigated the hypothesis that fascin-1 is a functional target of Rho in
normal and carcinoma cells, using experimental approaches that included a novel fluorescence resonance energy
transfer (FRET)/fluorescence lifetime imaging (FLIM) method to measure the interaction of fascin-1 with actin.
Results: Rho activity modulates the interaction of fascin-1 with actin, as detected by a novel FRET method, in
skeletal myoblasts and human colon carcinoma cells. Mechanistically, Rho regulation depends on Rho kinase
activity, is independent of the status of myosin II activity, and is not mediated by promotion of the fascin/PKC
complex. The p-Lin-11/Isl-1/Mec-3 kinases (LIMK), LIMK1 and LIMK2, act downstream of Rho kinases as novel
binding partners of fascin-1, and this complex regulates the stability of filopodia.
Conclusions: We have identified a novel activity of Rho in promoting a complex between fascin-1 and LIMK1/2
that modulates the interaction of fascin-1 with actin. These data provide new mechanistic insight into the
intracellular coordination of contractile and protrusive actin-based structures. During the course of the study, we
developed a novel FRET method for analysis of the fascin-1/actin interaction, with potential general applicability for
analyzing the activities of actin-binding proteins in intact cells.
Background
Cell protrusions are dynamic and morphologically varied
extensions of the plasma membrane, supported by the
actin cytoskeleton, that are essential for cell migration.
Fascin-1 is a prominent actin-bundling protein that char-
acterizes the filopodia, microspikes, and dendrites of
mesenchymal, neuronal, and dendritic cells, respectively,
and also contributes to filopodia, podosomes, and invado-
podia in migratory vascular smooth muscle cells and
cancer cells [1-4]. Fascin-1 is absent from most normal
adult epithelia, yet is upregulated in human carcinomas
arising from a number of tissues. There is evidence that
fascin-1 supports the migratory and metastatic capacities
of carcinomas [3-7]. Fascin-1 is an independent indicator
of poor prognosis in non-small-cell lung carcinomas and
colorectal, breast, and other carcinomas [4,8-11]. In colon,
breast, or prostate carcinomas, fascin-1 protein correlates
with increased frequency of metastasis [7,10,11]. Fascin-1
is thought to be the target of macroketone, which is under
investigation as an anti-cancer agent [10]. For these rea-
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fascin-1 in carcinoma cells has become an important focus
of research.
Actin bundling has been shown in vitro to be a con-
served activity of fascins [12-15]. In filopodia, fascin-1
molecules crosslink actin filaments into parallel bundles,
yet also move dynamically in and out of the bundle,
which may allow for bundle turning and bending [16].
F-actin cross linking by fascin-1 involves the N-terminal
and C- terminal domains of fascin-1, and a major
mechanism that inhibits the actin-bundling activity of
fascin-1 is the phosphorylation of an N-terminal motif
(S39 in human fascin-1) by conventional isoforms of
protein kinase C (cPKC) [17-19]. cPKC phosphorylation
of S39 inhibits actin binding and drives the formation of
a complex between phosphorylated fascin-1 and active
cPKC, resulting in a diffuse cytoplasmic distribution of
fascin-1 [18,20]. In migrating carcinoma cells, fascin-1
and cPKC associate dynamically in filopodia and at cell
edges, and the cycling of phosphorylated fascin-1 is
necessary for directional cell migration and experimental
metastasis [5,19]. Rac1 is a major upstream regulator of
both these activities of fascin-1; it promotes the bund-
ling of F-actin by fascin-1 in lamellipodia [21], and
drives the formation of a complex between phosphory-
lated fascin-1 and active cPKC, through a pathway
involving group I p21-activated kinases [19].
Effective cell migration depends on integration of the
F-actin cytoskeleton of protrusions with the contractile
actomyosin stress fibers in the cell body [22]. The molecu-
lar basis of this integration is not well understood, but fas-
cin-1 is known to associate with stress fibers under
conditions associated with moderate extracellular matrix
(ECM) adhesion, such as on mixed thrombospondin-1/
fibronectin (FN) surfaces or under conditions of partial
impairment of cell spreading on FN caused by a function-
pertubing antibody to a5 integrin [20,23,24]. In fish kera-
tocyes, fascin-containing filopodia contribute actin fila-
ment bundles into myosin II-containing stress fibers or
fold back to incorporate into lamellipodial F-actin arcs
[25]. The small guanine triphosphatase (GTPase) Rho is a
major regulator of cell contractility that acts antagonisti-
cally to Rac in several cellular pathways [26]. but whether
Rho regulates fascin-1 is unknown. Several lines of evi-
dence indicate functional links between fascin-1 protru-
sions and the contractile focal adhesions that are
promoted by active Rho; the phosphofascin-1/cPKC com-
plex regulates the balance between protrusions and focal
adhesions in mesenchymal cells, and depletion of fascin-1
from colon carcinoma cells inhibits focal adhesion disas-
sembly and prevents filopodia formation [5,18]. Whether
Rho participates in these processes is unknown. Although
overexpression of constitutively active Rho alters fascin-1
localization in quiescent fibroblasts, dominant-negative
Rho does not inhibit the long-lived fascin-1 protrusions of
cells adherent on thrombospondin-1 [21]. Tenascin-C,
another ECM glycoprotein that activates assembly of fas-
cin-1 protrusions, suppresses Rho activity in fibroblasts by
a syndecan-4 dependent pathway [27-30].
In this study, we investigated the hypothesis that fas-
cin-1 is a functional target of Rho and identified a path-
way from Rho via Rho kinases to p-Lin-11/Isl-1/Mec-3
kinases (LIMK)1 and LIMK2. We found that LIMK1/2 is
a novel positive regulator of the fascin-1/actin interaction
and is a novel interaction partner of fascin-1. These data
have important implications for consideration of the role
of fascin-1 in carcinoma metastasis.
Results
RhoA supports the interaction of fascin-1 with actin in
migrating cells
To investigate the novel hypothesis that Rho activity regu-
lates fascin-1, we used two cell systems: mouse C2C12
skeletal myoblasts and human SW480 colon carcinoma
cells. In both of these cell types, fascin-1-containing pro-
trusions are known to be important for ECM-dependent
cytoskeletal reorganizations and cell migration [5,20,31].
C2C12 mouse skeletal myoblasts adherent on FN undergo
transient ruffling during attachment and spreading,
followed by strong phosphorylation and complexing of
fascin-1 with conventional PKC as focal adhesions assem-
ble and then stabilize [14,27,31]. Thus, after 1 hour of
adhesion to FN, fascin-1 has a diffuse distribution, and
there are few fascin-1-positive cell protrusions (Figure 1A,
Con). In C2C12 cells treated with bisindolylmaleimide I
(BIM) to inhibit cPKC, fascin-1 was increased in bundles
at cell edges and was also aligned with stress fibers, con-
firming that PKC-dependent phosphorylation antagonizes
the actin-bundling capacity of fascin-1 [17-20] (Figure 1A).
FN-adherent C2C12 cells have significant levels of
endogenous active Rho-guanine triphosphate (GTP) rela-
tive to cells adherent to thrombospondin-1 (Figure 1B).
Under conditions of Rho inhibition by C3 exotoxin,
C2C12 cells adherent to FN have irregular shapes, with
increased fascin-1 bundles at cell edges (Figure 1A).
These observations were confirmed by scoring the num-
bers of peripheral fascin-containing bundles in adherent
cells. BIM or C3 treatments increased the number of
bundles, but did not alter the lengths of bundles contain-
ing fascin-1 (Figure 1C,D). Increased association of fas-
cin-1 with microfilament bundles within the cell body
was also seen in many C3-treated cells (Figure 1A). The
effects of BIM and C3 were confirmed in SW480 colon
carcinoma cells undergoing Rac-dependent migration on
laminin (LN) by mechanisms previously identified to
depend functionally on fascin-1-dependent filopodia,
dynamic fascin/PKC complexing, and focal adhesion
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Figure 1 Rho inhibition modulates peripheral fascin-containing protrusions. (A) C2C12 cells (control or treated with the indicated
pharmacological inhibitors), were plated onto 50 nmol/l fibronectin (FN) for 1 hour, then fixed and stained for fascin-1. Arrowheads indicate
examples of fascin-containing protrusions, dotted arrow indicates fascin in association with stress fibers. Boxed areas are enlarged below. Scale
bars, 10 μm. (B) Representative results of rhotekin-Rho-binding domain (RBD) pull-down of Rho-guanine triphosphate (GTP) from C2C12 cells
adherent on 30 nmol/l FN or thrombospondin-1 for 1 hour, or suspended for 90 minutes over BSA-coated plastic. (C,D) Quantification of (C)
numbers and (D) length of peripheral fascin bundles in C2C12 cells adherent for 1 hour on 50 nnmol/l FN after each treatment. Each column
represents the mean from 70 to 100 cells from 3 independent experiments; bars indicate SEM. *P < 0.001 versus control. (E) SW480 cells (control
or treated with the indicated pharmacological inhibitors), were plated onto 15 nnmol/l laminin (LN) for 2 hours, then fixed and stained for
fascin-1. Arrowheads indicate examples of fascin-containing protrusions; boxed areas are enlarged below. Scale bars, 10 μm.
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turnover [5,15]. BIM treatment of SW480 cells on LN
resulted in more irregular morphologies with non-polar-
ized formation of fascin-1-positive protrusions at cell
margins (Figure 1E). SW480 typically contain relatively
few stress fibers, and the effects of C3 on fascin-1 relocali-
zation to cell edges was less pronounced in these cells
(Figure 1E, insets). Rho activity in migrating SW480 cells
and its effective inhibition by C3 exotoxin was confirmed
by measurement of RhoA activity under the different
experimental conditions (see Additional file 1, Figure S1A).
Together, these data implicate Rho activity in regulation of
the dynamic balance of fascin-1 interactions with F-actin.
To obtain precise evidence that Rho activity can regulate
fascin-1, we tested the effect of Rho inhibition on the
interaction of fascin-1 with actin, using fluorescence life-
time imaging microscopy (FLIM) to measure fluorescence
resonance energy transfer (FRET). The abundance of actin
in cells, coupled with issues of the conformational avail-
ability of fluorophores, has so far hindered attempts to
measure interactions between fluorescently-tagged actin
and its binding partners by FRET/FLIM. Thus, to measure
the fascin-1/actin interaction directly, we took a novel
approach, using green fluorescent protein (GFP)-tagged
lifeact as the FRET donor. Lifeact is a peptide of 17 amino
acids, which is derived from yeast, and binds specifically
and reversibly to F-actin in live cells without interfering
with actin dynamics [32]. To set up conditions to measure
the fascin-1/actin interaction without modulation or inter-
ference by dynamic fascin-1 phosphorylation, we used as
the FRET acceptor in these experiments a fascin-1 mutant,
fascin-1S39A, which binds actin but does not interact with
cPKC [18,19], The monomeric red fluorescent protein
(mRFP)-tagged fascin-1S39A showed strong FRET with
GFP-lifeact in both FN-adherent C2C12 cells and SW480
cells on LN (Figure 2A,B (Con cells); Figure 2C shows
quantification from multiple cells). FRET efficiency
between GFP-lifeact and mRFP-fascin1S39A was strong at
the cell peripheries and was also often detected in cell
bodies (Figure 2A.B; Con cells). The interaction of phos-
phomimetic mRFP-fascin-1S39D was minimal, with the
GFP fluorescence lifetime comparable with that of cells
expressing GFP-lifeact alone (shown for SW480 cells:
Figure 2B,C). To confirm that the GFP-lifeact results were
an accurate reflection of the distribution of F-actin in cells,
cells co-expressing GFP-lifeact and mRFP-fascin1S39A
were co-stained with phalloidin to visualize total F-actin,
and then analyzed by FLIM. Analysis of the cell edges
showed that the highest GFP-lifeact signals were found
within areas with the highest intensity of phalloidin stain-
ing, thus corresponding to concentrations of F-actin (see
Additional file 1, Figure S1B,C), and mRFP-fascin-1 was
similarly distributed (see Additional file 1, Figure S1C).
The areas of highest FRET efficiency occurred within the
areas of highest intensity phalloidin staining, and
overlapped partially with the concentrations of GFP-lifeact
(see Additional file 1, Figure S1C). Thus, the FRET/FLIM
interaction accurately reflects the portion of total F-actin
that is involved in fascin-1 binding.
As expected from the initial experiments (Figure 1),
treatment with BIM or C3 resulted in altered cell
morphologies (Figure 2A,B). C3-treated C2C12 cells
typically showed reduction of actin stress fibers within
cell bodies (Figure 2A). BIM treatment did not prevent
the fascin-1S39A/lifeact FRET/FLIM interaction, con-
firming the independence of this interaction from cPKC
activity (Figure 2). In both cell types, the interaction
between GFP-lifeact and mRFP-fascin-1S39A was
strongly dependent on Rho activity (Figure 2A-C (C
shows quantification from multiple cells)). These FRET
data confirm that the direct interaction of fascin-1 with
actin can be imaged using GFP-lifeact as a probe for F-
actin, and that the interaction occurs preferentially with
non-phosphorylated fascin-1 in intact cells. They also
reveal that Rho acts in intact, ECM-adherent cells to
promote the interaction of fascin-1 with actin.
Rho inhibition does not alter levels of the fascin-1/cPKC
complex
To establish whether the mechanism by which Rho pro-
motes the fascin-1/actin interaction affects the fascin-1/
cPKC complex, which is a known negative regulator of
actin-bundling by fascin-1, cell protrusions, and cell
migration [5,18,19], we carried out FRET/FLIM measure-
ments for the interaction of GFP-fascin-1 with cPKC-
mRFP in control or inhibitor-treated cells. Both C2C12
and SW480 contain cPKC; PKCa predominates in C2C12
cells and PKCg in SW480 cells [19,20]. When activated,
both isoforms interact with phospho-fascin-1 [18,19]. In
both cell types, the fascin-1/cPKC interaction was abol-
ished in BIM-treated cells, confirming that this interaction
depends on catalytically active cPKC (Figure 3A-C (C
shows quantification from multiple cells)) [19]. However,
C3 treatment did not alter the FRET efficiency signifi-
cantly from that of control cells (Figure 3A-C). Strong
decreases in GFP fluorescence lifetime, indicative of high
FRET efficiency, remained detectable at the cell edges and
in cell bodies (Figure 3A,B). Thus, under native cell condi-
tions, Rho activity promotes the fascin-1/actin interaction
(Figure 2), but is neutral for the fascin-1/cPKC interaction
that is a known antagonist of F-actin bundling by fascin-1.
These data suggest that the Rho-dependent pathway
involves a novel form of regulation of fascin-1.
Modulation of the fascin-1/actin interaction by Rho
depends on Rho kinases but not on myosin-based
contractility
To identify molecular components downstream of Rho
in this novel pathway, we tested the effect of inhibiting
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Rho effectors that are known mediators of actin-based
cell contractility. C2C12 and SW480 cells each express
both isoforms of Rho-associated coiled-coil-forming
kinases (Rho kinases I and II) (see Additional file 2,
Figure S2A). Y27632 treatment, which inhibits Rho
kinases, strongly inhibited the GFP-lifeact/mRFP-fascin-
1S39A interaction in both cell types (Figure 4A shows
quantification from multiple cells; for examples of
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Figure 2 Rho activity promotes the interaction of fascin-1 with actin: detection by a novel fascin-1/lifeact fluorescence resonance energy
transfer (FRET) system. (A,B) Measurement of the interaction of monomeric red fluorescent protein (mRFP)-fascin-1S39A with green fluorescent
protein (GFP)-lifeact in (A) C2C12 cells on fibronectin (FN) or (B) SW480 cells on laminin (LN). Cells transiently transfected with the indicated
plasmids were plated on (A) FN for 1 hour, or (B) LN for 2 hours, without or with pre-treatment with the indicated inhibitors, then fixed, mounted,
and imaged using fluorescence lifetime imaging microscopy (FLIM) to measure FRET. In each panel, intensity multiphoton GFP (donor) images are
shown with the corresponding epifluorescence image for mRFP (acceptor). (B) Representative images of GFP and lifetime plot in the absence of an
acceptor, or in presence of mRFP-fascin-1S39D, which does not bundle F-actin. In each panel, lifetime images are presented in a blue-to-red
pseudocolor scale with red as short lifetime. (C),Percentage FRET efficiency under each experimental condition. Each column represents the mean
from eight to twelve cells per condition and three independent experiments; bars indicate SEM. *P < 0.001 versus control.
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Figure 3 Rho activity does not modulate the interaction of fascin-1 with conventional protein kinase C (cPKC). (A) Measurement of the
interaction of green fluorescent protein (GFP)-fascin-1 with PKCa- monomeric red fluorescent protein (mRFP) in C2C12 cells on fibronectin (FN).
(B) Measurement of the interaction of green fluorescent protein (GFP)-fascin-1 with PKCg-mRFP in SW480 cells on laminin (LN). Cells transiently
transfected with the indicated plasmids were plated on (A) FN for 1 hour, or (B) LN for 2 hours, without or with pre-treatment with the
indicated inhibitors, then fixed, mounted, and imaged using fluorescence lifetime imaging microscopy (FLIM) to measure fluorescence resonance
energy transfer (FRET). In each panel, intensity multiphoton GFP (donor) images are shown with the corresponding epifluorescence image for
mRFP (acceptor). Lifetime images are presented in a blue-to-red pseudocolor scale with red as short lifetime. (C), Percentage FRET efficiency
under each experimental condition. Each column represents the mean from eight to twelve cells per condition and three independent
experiments; bars indicate SEM.*P < 0.01 versus control.
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Figure 4 Rho kinase activity promotes the interaction of fascin-1 with actin. (A) Percentage FRET efficiency of the interaction of
monomeric red fluorescent protein (mRFP)-fascin-1S39A with green fluorescent protein (GFP)-lifeact in SW480 cells on laminin (LN) under
control conditions or after inhibition of Rho kinases by Y27632. Each column represents the mean from eight to twelve cells per condition and
three independent experiments; bars indicate SEM. *P < 0.05 versus control. (B) Confocal images of the same non-fixed SW480 cell transiently
expressing GFP-lifeact, before and after treatment with Y27632 (see Additional file 4, movie 1). The boxed 25 × 25 μm regions in the lefthand
panels are enlarged in the zoomed right panels. Scale bars, 10 μm. (C,E) Fascin-1 and F-actin dynamics in SW480 cells transiently expressing
GFP-fascin-1 and mRFP-lifeact, (C) without or (E) with Y27632 treatment (see Additional files 5 and 6, movies 2 and 3). (C,E) Left panels show
representative cells from four independent confocal time-lapse movies. Scale bars, 10 μm. Right panels show zoomed images from the boxed 10
× 15 μm regions in the lefthand panels. (D,F) Fluorescence line-scan analysis of GFP-fascin-1 and mRFP-lifeact in a single filopodium from (D)
control, or (E) Y27632-treated cells at three timepoints (i to iii). (C,E) Yellow arrows indicate the filopodia analyzed; (E) arrowheads indicate
another example of an unstable filopodium. Scale bars, 10 μm.
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individual cells, see Additional file 2, Figure S2B). The
Y27632-treated cells resembled C3-treated cells in
having irregular morphologies (see Additional file 2,
Figure S2B). Confocal immunofluorescence microscopy
for endogenous fascin-1 showed that Y27632-treated
C2C12 cells on FN had more irregular morphologies,
with fascin-containing protrusions around the cells
(Figure 5A), again resembling the morphology of C3-
treated C2C12 cells (Figure 1A). Similarly, F-actin orga-
nization at cell edges (as visualized by GFP-lifeact in
SW480 cells imaged by time-lapse before and after
Y27632 addition) was altered from protrusive lamellipo-
dial edges and linear filopodia in control cells to flexible
filopodia around cell margins after Y27632 treatment
(Figure 4B, shown for the same cell before and after
Y27632 addition; also see Additional file 3, movie 1).
These protrusions were confirmed to be de novo filopo-
dia, not retraction fibers, because they were assembled
as new protrusions and stabilized throughout the course
of the time-lapse experiments (see Additional file 3,
movie 1).
The effects of Y27632 treatment were analyzed further by
confocal time-lapse imaging of live SW480 cells co-expres-
sing GFP-fascin-1 and mRFP-lifeact, in order to enable
clear visualization of fascin-positive filopodia. In control
cells, all filopodia contained both fascin-1 and lifeact
(Figure 4C; for single-channel images, see Additional
file 2, Figure S2C). Individual filopodia initiated, extended,
and retracted over 1 to 3 minutes (Figure 4C, arrows; also
see Additional file 4, movie 2). Line-scan analysis of fluor-
escence intensities for GFP-fascin-1 and mRFP-lifeact
along the length of individual filopodia showed a strong
fascin-1 signal along the entire length of the shaft of each
filopodium, and a progressive reduction in the lifeact sig-
nal towards the tip (Figure 4D). The filopodia of Y27632-
treated cells were less linear, remained extended over a
longer timescale (Figure 4E shows filopodium at time-
points i to iii (arrow); see Additional file 5, movie 3), and
had reduced fascin-1 intensity along the length of each
filopodium (Figure 4E; see Additional file 2, Figure S2C
for single-channel images). Thus, the Y27632-induced
bending and altered dynamics of filopodia are probably
due to alterations in organization of the core actin bundle
of each filopodium and to the expected alteration in cell-
body contractility caused by reductions in contractile
stress fibers.
Another major mediator of cell contraction is myosin
light chain kinase, (MLCK) [33]. To establish whether
either MLCK or myosin activity act to inhibit actin bund-
ling by fascin-1, FN-adherent C2C12 cells were treated
with ML-7 as an inhibitor of MLCK, or 2,3-butanedione
monoxime (BDM) as a broad-spectrum inhibitor of acto-
myosin, which has also been reported to act as a chemical
phosphatase [34]. In contrast to the Y27632 treatment,
no enhancement of endogenous fascin-1 in peripheral
bundles was detected, indicating that the inhibitory activ-
ity of Rho kinases is not mediated by myosin-based con-
tractility (Figure 5A; Figure 5C shows quantification of
multiple cells). Similarly, expression of a dominant-
negative truncated caldesmon that blocks stress-fiber
assembly [35] did not promote peripheral fascin-1/actin
bundles (Figure 5B; Figure 5C shows quantification of
multiple cells). The possible roles of MLCK and myosin
ATPase were also examined by FRET/FLIM analysis of
SW480 cells co-expressing GFP-lifeact and mRFP-fascin-
1S39A. Neither ML-7 nor blebbistatin (the latter tested
as a specific inhibitor of myosin II ATPase) inhibited
the interaction between fascin-1 and actin (Figure 5D;
Figure 5E shows quantification of multiple cells). Thus,
under native conditions, Rho activity promotes the inter-
action of fascin-1 with actin through a Rho kinase-
dependent, myosin II-independent mechanism.
Fascin-1/actin binding is promoted by interaction of
fascin-1 with LIM kinases
Having identified from the above experiments that a Rho/
Rho kinase/fascin-1 pathway is active in two distinct cell
types, our further experiments focused on SW480 cells
migrating on LN, for which signaling regulation of fascin-
1 has been studied extensively [5,19]. Because the activity
of Rho kinases on fascin-1 is not mediated by myosin-
based contractility, we first investigated if fascin-1 might
interact with a Rho kinase. SW480 express Rho kinases I
and II (see Additional file 2, Figure S2A). However, using
FLIM analysis, there was no FRET seen between mRFP-
fascin-1S39A or mRFP-fascin-1S39D with either GFP-Rho
kinase I or GFP-Rho kinase II. Furthermore, neither Rho
kinase I nor Rho kinase II co-immunoprecipitated with
either endogenous or overexpressed fascin-1 in SW480
cells, or with purified hexahistidine-tagged fascin-1, and
fascin-1 was not a substrate in Rho kinase assays in vitro
(data not shown). We conclude that fascin-1 is not a direct
binding partner of Rho kinase I or II.
The LIM kinases, LIMK1 and LIMK2, are well-estab-
lished substrates and effectors of Rho kinases. LIMK1/2
are dual-specificity kinases that function in organization of
the actin and microtubule cytoskeletons, cell-motility pro-
cesses including cancer metastasis, and cell cycle progres-
sion [36]. In migrating SW480 cells, endogenous LIMK1
and LIMK2 are located in the cytoplasm and at protrusive
edges, where GFP-fascin-1 (expressed at very low levels
under a truncated cytomegalovirus (CMV) promoter,
‘specGFP’; see Methods) also concentrates (see Additional
file 6, Figure S3A). To test for a possible direct interaction
between fascin-1 and LIMK1/2, a FRET/FLIM assay was
set up. In SW480 cells, robust FRET was detected between
mRFP-fascin-1S39A and either GFP-LIMK1 or GFP-
LIMK2 (Figure 6A-C). The interactions were also analyzed
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Figure 5 Rho kinase activity promotes peripheral fascin-containing protrusions via a myosin-independent process. (A) Confocal images
of C2C12 cells after 1 hour of adhesion to 50 nmol/l fibronectin (FN), either untreated or pretreated with specified inhibitors, fixed and stained
for fascin-1. Arrowheads indicate examples of peripheral fascin-actin bundles in Y27632-treated cells. Scale bars, 10 μm. (B) Confocal images of
C2C12 cells transiently expressing green fluorescent protein (GFP)-caldesmon or an inactive GFP-caldesmon-445 mutant after 1 hour of adhesion
to 50 nmol/l FN. Cells were fixed and stained either for F-actin (left panels) or fascin-1 (right panels). In the anti-fascin-1 stained samples,
arrowheads indicate the transfected cells. Scale bars, 10 μm. (C) Quantification of peripheral fascin-1 bundles/cell under the conditions shown in
(A) and (B). Data are from 75 to 125 cells/condition and 3 independent experiments. *P < 0.001 versus control. (D) Measurement of the
interaction of mRFP-fascin-1S39A with GFP-lifeact in SW480 cells on laminin (LN). Cells transiently transfected with the indicated plasmids were
plated on LN for 2 hours, without or with pre-treatment with the indicated inhibitors, then fixed, mounted, and imaged using fluorescence
lifetime imaging microscopy (FLIM) to measure fluorescence resonance energy transfer (FRET). In each panel, Intensity multiphoton GFP (donor)
images are shown with the corresponding epifluorescence image for mRFP (acceptor). Lifetime images are presented in a blue-to-red
pseudocolor scale with red as short lifetime. (E) Percentage FRET efficiency under each experimental condition. Each column represents the
mean from fourteen cells per condition and three independent experiments; bars indicate SEM.
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Figure 6 Rho-dependent and Rho kinase-dependent interaction of fascin-1 with p-Lin-11/Isl-1/Mec-3 kinase (LIMK) (A,B). Measurement
of the interaction of (A) green fluorescent protein (GFP)-LIMK1 (A), or (B) GFP-LIMK2, with monomeric red fluorescent protein (mRFP)-fascin-
1S39A in SW480 cells on laminin (LN). Cells transiently transfected with the indicated plasmids were plated on LN for 2 hours, without or with
pre-treatment with the indicated inhibitors, then fixed, mounted, and imaged using fluorescence lifetime imaging microscopy (FLIM) to measure
fluorescence resonance energy transfer (FRET). In each panel, intensity multiphoton GFP (donor) images are shown with the corresponding
epifluorescence image for monomeric red fluorescent protein (mRFP) (acceptor). Lifetime images are presented in a blue-to-red pseudocolor
scale with red as short lifetime. (C), Percentage FRET efficiency under each experimental condition. Each column represents the mean from nine
to sixteen cells per condition and three independent experiments; bars indicate SEM. *P < 0.01 versus control; **P < 0.005 versus control. (D)
Representative immunoblots from pull-downs of SW480 cell lysates with hexahistidine (6His)-tagged fascin-1 (wild-type (WT), S39A or S39D)
bound to nickel-agarose beads. (E) Quantification of LIMK1 binding to fascin-1 bead matrices. For each matrix, LIMK1 binding was ratioed to
binding to the bead-only matrix, based on quantification of grayscale images in ImageJ software (http://rsb.info.nih.gov/ij/download.html). Each
column represents mean values from three independent experiments; bars indicate SEM. (F) Demonstration that LIMK1 binding to 6His-fascin-1
depends on Rho and Rho kinase activities. Representative of three independent experiments. (D,F) Molecular markers are in kDa.
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using GFP-fascin-1 as the FRET donor and mRFP-LIMK1
as the acceptor (data not shown). Interaction of mRFP-fas-
cin-1S39A with either LIMK 1 or LIMK2 was inhibited in
cells treated with either C3 or Y27632, confirming that the
interaction depends on active Rho small GTPase and Rho
kinases (Figure 6A-C). Rho kinases activate LIMK by
phosphorylation of threonine 508 (in LIMK1) or threonine
505 (in LIMK2); this induces LIMK dimerization, autop-
hosphorylation, and catalytic activation [36-38]. As
expected, the levels of activated pT508/T505 LIMK1/2
were sharply decreased in cells treated with C3 or Y27632
(see Additional file 6, Figure S3B).
To confirm the novel fascin-1/LIMK1/2 interaction by an
independent biochemical method, and to investigate
whether the S39 phosphorylation site of fascin-1 has a
role in the interaction, hexahistidine (6His)-tagged fascin-
1 (wild-type), or 6His-fascin-1 with point mutations of
S39 were expressed in Escherichia coli, purified with
metal-affinity beads, and matched amounts loaded onto
fresh metal-affinity beads. Equal protein loadings of
SW480 cell lysate were passed over the beads, and bound
candidate proteins were identified by immunoblotting
after extensive washing. Relative to a control bead matrix,
LIMK1 was found to bind to all three forms of fascin-1,
indicating that S39 phosphorylation of fascin-1 does not
control this interaction (Figure 6D; Figure 6F shows
quantification from multiple cells). However, some
enrichment of LIMK1 on fascin-1S39A matrix was
detected across multiple experiments (Figure 6F). Active
LIMK1/2 bound to both the wild-type and mutant fas-
cin-1 proteins, as detected with an antibody to T508/
T505-phosphorylated LIMK1/2 (Figure 6D). Very low
levels of LIMK2 were detected in SW480 cells, and
LIMK2 binding to 6His-fascin-1 was not detected (Figure
6D). The LIMK1 interaction with fascin-1 was specific,
because binding of Rho kinase I or II was not detected
(Figure 6D) in agreement with the previous FRET ana-
lyses of possible Rho kinase binding to fascin-1. Also in
agreement with the FRET data, lysates from cells treated
with C3 exotoxin or Y27632 showed reduced binding of
LIMK1 to 6His-fascin-1 (Figure 6E). This result again
indicates the importance of LIMK1 activation for its
binding to fascin-1. The combined FRET and biochemical
data show that Rho-dependent regulation of the fascin-1/
actin interaction is achieved by activation of LIMK1/2
and an unsuspected direct interaction of fascin-1 with
LIMK1/2.
The fascin-1/LIMK1/2 interaction depends on LIMK1/2
activation and modulates filopodia dynamics
To study the mechanism and functional role of the fascin-
1/LIMK interaction in carcinoma cells, we first measured
interactions of non-activatable (T508A) or catalytically
inactive (D460A) forms of GFP-LIMK1 with mRFP-fascin-
1 by FRET/FLIM in SW480 cells migrating on laminin.
The catalytic activity of LIMK1 was not required for the
interaction. By contrast, LIMK1T508A showed signifi-
cantly reduced FRET with fascin-1. The phosphomimetic
mutant, LIMK1T508D, had a similar level of FRET to that
of wild-type LIMK1 (Figure 7A; Figure 7B shows quantifi-
cation from multiple cells). Thus, the activating phosphor-
ylation of LIMK1T508 is important for the interaction of
LIMK1 with fascin-1. To relate these findings to filopodia
assembly, the possible co-localization of wild-type or fas-
cin-binding or non-binding mutant forms of GFP-LIMK1
with mRFP-fascin-1 was examined by confocal micro-
scopy. Fascin-1 was located along the length of each linear
filopodium, and LIMK1 was detected at the base of filopo-
dia (Figure 7C; see Additional file 6, Figure S3C). Similar
observations were made with cells co-expressing mRFP-
lifeact and GFP-LIMK1 (see Additional file 6, Figure S3D).
These observations are in line with other reports on the
cellular localization of LIMK1: typically, LIMK1/2 are
mostly cytosolic, without bulk co-localization with the
actin cytoskeleton or substrates such as cofilin [39,40].
Cells expressing GFP-LIMKT508A showed fascin-1/LIMK
co-localization in some areas of protrusions (Figure 7C),
while cells expressing GFP-LIMK1D460A had fewer filo-
podia that contained less fascin-1 (Figure 7C, D). As quan-
tified from the static images, cells expressing GFP only,
GFP-LIMK1, or GFP-LIMK1T508A formed equivalent
numbers of filopodia, and in each case the filopodia were
around 3 μm in length (Figure 7C,D). In cells expressing
GFP-LIMK1D460A, the few filopodia that formed were
around 2 μm in length (Figure 7C,D).
The requirement for kinase activity of LIMK1/2 in filo-
podia formation is in line with the known roles of
LIMK1/2 in stabilization of F-actin cytoskeleton
[36,41,42]. The effects of expression of wild-type or
mutant LIMK1 on filopodia dynamics in migratory
SW480 cells were therefore examined by time-lapse con-
focal microscopy. Kymography was also carried out to
visualize physical displacement of individual filopodia
over time. Compared with cells expressing GFP only, the
filopodia of GFP-LIMK1-expressing cells had a longer
life (Figure 8A, B), as measured by reduced displacement
of the tips of filopodia over time (Figure 8E; Figure 8F
shows quantification from multiple cells; see Additional
file 7, movie 4; see Additional file 8, movie 5). By con-
trast, the filopodia of cells expressing GFP-LIMK1T508A,
which does not interact with fascin-1, had motility
equivalent to the filopodia of control cells (Figure 8C; see
Additional file 9, movie 6). Cells expressing catalytically
inactive GFP-LIMK1D460A initiated filopodia that col-
lapsed and did not persist, thus leading to fewer and
smaller filopodia, in agreement with the static images
(Figure 8D; see Additional file 10, movie 7). The motility
and displacement over time of the few filopodia that did
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Figure 7 Activation of p-Lin-11/Isl-1/Mec-3 kinase (LIMK)1 leads to its interaction with fascin-1 and affects formation of filopodia. (A)
Measurement of the interaction of wild-type or mutant forms of green fluorescent protein (GFP)-LIMK1 with monomeric red fluorescent protein
(mRFP)-fascin-1 in SW480 cells on laminin (LN). Cells transiently transfected with the indicated plasmids were plated on LN for 2 hours, then
fixed, mounted, and imaged using fluorescence lifetime imaging microscopy (FLIM) to measure fluorescence resonance energy transfer (FRET).
Intensity multiphoton GFP (donor) images are shown with the corresponding epifluorescence image for mRFP (acceptor). Lifetime images are
presented in a blue-to-red pseudocolor scale with red as short lifetime. (B) Percentage FRET efficiency under each experimental condition. Each
column represents the mean from fourteen to seventeen cells per condition and three independent experiments; bars indicate SEM. *P = 0.001
versus wildtype. (C) Role of LIMK1 activity in organization of filopodia. Live SW480 cells transiently transfected with GFP alone or GFP-LIMK1
(wild-type (WT), D460A or T508A) and mRFP-fascin-1, and protein localizations and cell edges were imaged using confocal microscopy.
Arrowheads indicate points where GFP-LIMK1 and mRFP-fascin-1 colocalize in filopodia. Scale bars, 10 μm. (D) The number/cell and (E) length of
filopodia were counted from images obtained as in (C), from 12 to 20 cells per condition and 4 independent experiments. *P < 0.05 versus GFP
control. See Additional files 9 and 10 (movies 6 and 7) for the effects of LIMK1 mutants on filopodia.
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form in GFP-LIMK1D460A-expressing cells were equiva-
lent to the behavior of filopodia of control cells (Figure
8F, see Additional file 10, movie 7). Thus, promotion of
the fascin-1/actin interaction stimulates the stability and
persistence of filopodia.
Discussion
Several lines of indirect evidence have linked the forma-
tion of fascin-containing cell protrusions with the status
of actomyosin contractility or focal adhesions, but the
processes involved, in particular the role of Rho GTPase,
have remained obscure. In this study, we established,
with multiple lines of evidence, that Rho activity modu-
lates the ability of fascin-1 to interact with actin in both
normal and carcinoma-derived cells. The discovery of
this novel function of Rho was advanced by the develop-
ment of a novel assay to measure the fascin-1/actin
interaction by FRET/FLIM microscopy. In this assay, a
small, actin-binding peptide, lifeact, was adopted as the
FRET donor. Lifeact binds reversibly to F-actin, and
thus FRET with fascin-1 takes place only when both
molecules are in close proximity (<10 nm) and bound to
filamentous actin. The specificity of the interaction mea-
sured was established by: 1) the lack of FRET interaction
of lifeact with the non-actin-bundling form of fascin-1,
fascin-1S39D; 2) the independence of fascin-1/lifeact
FRET from PKC kinase activity, and 3) the correspon-
dence of lifeact distribution and fascin-1/lifeact FRET
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Figure 8 The fascin-1/p-Lin-11/Isl-1/Mec-3 kinase (LIMK)1 interaction promotes stabilization of filopodia. (A-D) Images from confocal
time-lapse movies of cells expressing mRFP-fascin-1 with (A) green fluorescent protein (GFP), (B) GFP-LIMK1 (B), (C) GFP-LIMK1T508A or (D) GFP-
LIMK1D460A. see Additional files 7 to 10 (movies 4 to 7). There were 15 to 25 cells per condition analyzed in 4 independent experiments. and
cells from representative movies are shown. (A-D) Boxed 15 × 15 mm regions in the lefthand panels are enlarged in the images from a series of
time points in the right panels. See Additional file 3, Figure S3, for single-channel images from (A) and (B). Scale bars, 10 μm. (E) Kymographs of
representative filopodia from cells co-expressing GFP or GFP-LIMK1 and mRFP-fascin-1. Displacement of filopodia was measured in accordance
with the maximum change in position of filopodial tips over 2 minutes, as indicated by the dotted yellow lines. (F) Quantification of the
maximum displacement of filopodia from cells expressing GFP, or wild-type or mutant GFP-LIMK1 and mRFP-fascin-1. Each column represents
the mean from five filopodia from at least five cells per condition in four independent experiments; bars indicate SEM. *P < 0.001 versus GFP
control.
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Using the combined approaches of immunofluores-
cence microscopy, time-lapse imaging of cells expressing
GFP-fascin-1, and the novel FRET assay, we found that
inhibition of either Rho or its effectors Rho kinase I and
II resulted in inhibition of the fascin-1/lifeact interaction
as measured by FRET/FLIM. According to the indirect
immunofluorescence of endogenous F-actin or fascin-1
and the imaging of live cells expressing GFP-fascin-1,
inhibition of either Rho or Rho kinases also altered cell
morphology and led to the formation of more protru-
sions containing fascin-1 at cell edges. When analyzed in
detail by confocal time-lapse microscopy, the filopodial
activity of Y27632-treated cells was seen to occur within
regions of increased membrane ruffling. These filopodia
had distinct characteristics: GFP-fascin-1 was not loca-
lized strongly along the filopodial shaft; the filopodia
were less straight, probably as a result of loss of actin-
bundle rigidity caused by decreased localization of fascin-
1 towards filopodial tips (Figure 4), and the lifetimes of
these filopodia were longer (Figure 4; see Additional
file 3, movie 1; see Additional file 4, movie 2; see Addi-
tional file 5, movie 3).
The FRET assay studies a specific molecular interaction
within the overall assembly/disassembly dynamics of pro-
trusions. Because Rho kinase inhibition of SW480 migra-
tion on LN is fascin-1-independent [5], it is likely that
control of protrusion number has a multifactorial basis,
for example, it may be linked to both actomyosin-based
cell tension and chemical signaling. Inhibition of Rho or
Rho kinases is well known to inhibit stress-fiber microfi-
lament bundles within cell bodies [43,44]; however, in
our experiments, many cells treated with these inhibitors
displayed increased association of fascin-1 with cell-body
microfilament bundles. Fascin-1 and tropomyosin act as
antagonists for actin binding, and previous studies of
ECM-adherent cells have indicated preferential associa-
tion of fascin-1 with cell-body microfilament bundles in
cells under conditions of reduced focal adhesion assem-
bly and contractility [4,20,24]. Treatments with C3 toxin
or Y27632 are likely to lead to similar conditions of
reduced cell contractility in adherent cells.
By combining the new lifeact FRET assay with bio-
chemical analyses of cell extracts, we have identified
Rho-dependent regulation as a novel signaling process
that affects both fascin-1 and the fascin-1/actin interac-
tion. Importantly, the mechanistic basis for the pathway
downstream of Rho and Rho kinases resides in a pre-
viously unidentified process, the interaction of LIMK1/2
with fascin-1. Both of the LIMK isoforms are expressed
in many tissues, although specificity of expression pat-
terns and subcellular localizations has been described
[37,45,46]. In this study, we identified the interaction of
fascin-1 with active LIMK1/2 in SW480 cells by bio-
chemical pull-down from cell extracts and by FRET/
FLIM in intact, migrating cells. As established by the
immunoblots, fascin-1 pull-down experiments, confocal
microscopy, and FRET/FLIM analysis for LIMK1, the
mechanism of the interaction depends on LIMK1 activa-
tion by Rho kinase phosphorylation, but is independent
of the status of S39-phosphorylation of fascin-1. Both
S39-phosphorylated and non-phosphorylated fascin-1 are
needed for efficient migration of SW480 cells [5], and
these new data suggest that the LIMK1/fascin-1 interac-
tion is a possible mechanism to retain S39-phosphory-
lated fascin-1 in proximity to actin structures at cell
edges. We found that fascin-1 localized in filopodia in
cells expressing wild-type or T508A mutant forms of
LIMK1; however, only wild-type LIMK1 was competent
to stabilize filopodia. LIMK1-T508A, which did not inter-
act with fascin-1 in the FRET assay, did not increase filo-
podial persistence. Thus the LIMK1/fascin-1 interaction
contributes to the stability of filopodia. As reported pre-
viously [41,42], expression of kinase-dead LIMK1
reduced in decreased numbers of filopodia, and the
remaining filopodia were not stabilized.
Overall, these results identify a novel pathway that regu-
lates actin-binding by fascin-1, with functional conse-
quences for filopodial stability (Figure 9). Regulation of the
fascin-1/actin interaction did not depend on activity of
MLCK or on myosin ATPase activity, and is thus separ-
able from the status of actomyosin contractility.
Figure 9 Model for the novel pathway that regulates fascin-1/
actin interaction and filopodia stability. See Discussion for
details. As shown in Figure 6, active p-Lin-11/Isl-1/Mec-3 kinase
(LIMK)1/2 bound to both S39-phosphorylated and non-
phosphorylated fascin-1.
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Similar to fascin-1, LIMK1 and LIMK2 contribute func-
tionally to cancer cell invasion and metastasis, and are
therefore of interest as therapeutic targets [36,47,48]. Thus,
fascin-1 and LIMK1/2 might co-operate to promote protru-
sions and cell motility if they are co-expressed in tumors.
For example, LIMK1/2 overexpression is well known to
increase F-actin, protrusions, and stress fibers in various
cells, and correspondingly, LIMK1/2 knockdown or expres-
sion of kinase-dead LIMK1/2 decreases F-actin stability,
filopodia/lamellipodia, and cell migration [41,42,48]. We
propose that the cell protrusion phenotypes observed after
LIMK1/2 inhibition may, in part, be mediated by reduced
actin binding and bundling by fascin-1. Interestingly,
LIMK1/2 are also downstream effectors of p21-activated
kinases (PAK), which, as we have previously shown regulate
formation of the fascin-1/cPKC complex in colon carci-
noma cells, and which also correlate clinically with meta-
static progression [19,49]. Thus, LIMK1/2 might represent
a nexus between several pathways that regulate the ability
of fascin-1 to participate in different protein complexes.
A well-characterized substrate of LIMK1/2 is cofilin, an
actin-binding protein that acts to depolymerise F-actin
by its actin-severing activity. Phosphorylation of cofilin
on ser-3 by LIMK1/2 inhibits its severing activity, result-
ing in the aforementioned stabilization or reorganization
of actin structures [50-52]. Similar to fascin-1, the cofilin
pathway has been linked to breast-cancer metastasis [50].
It was recently shown that cofilin associates transiently
with retracting filopodia, and that its actin-severing activ-
ity is enhanced on actin bundles crosslinked by fascin-1
[53]. The relationship between the fascin-1/LIMK1/2
complex and cofilin in the dynamics of filopodia are
questions of future interest. It will be important to estab-
lish if fascin-1 competes with cofilin for LIMK1 kinase
availability, thereby modulating actin dynamics directly,
or whether LIMK1/2 act directly or indirectly as a scaf-
fold to maintain fascin-1 in proximity to F-actin. Alterna-
tively, fascin-1 binding might inhibit the kinase activity of
LIMK1/2, thereby affecting actin dynamics indirectly, as
previously shown for nischarin [54]. LIMK1 contributes
to the transcriptional activity of serum response factor
[55], and it will be interesting to determine if this activity
is modulated by fascin-1.
Conclusions
In this study, we have identified a novel activity of the
small GTPase Rho in promoting the interaction of fas-
cin-1 with actin in ECM-adherent, migratory cells. Rho,
Rho kinases, and LIMK1/2 were identified as key effec-
tors, and activated LIMK1 or LIMK2 act as novel bind-
ing partners of fascin-1. These findings have many
implications for our understanding of how fascin-1 pro-
tein complexes and actin dynamics are coordinated in
contractile and protrusive actin-based structures in
intact cells, and may be particularly relevant to carci-
noma cell migration and metastasis. In the course of the
study, we developed a novel method for analysis of the
fascin-1/actin interaction by FRET/FLIM. This method
has potential general applicability for analyzing the
activities of actin-binding proteins in intact cells.
Methods
Cell lines and materials
C2C12 mouse skeletal myoblast and SW480 human colon
carcinoma cells were from the American Type Culture
Collection (ATCC). GFP-fascin-1 and PKCg-mRFP con-
structs were prepared as previously described [15,17].
PKCa-mRFP [56] was a gift from T. Ng, and the GFP-
tagged forms of LIMK1, LIMK2 [57], ROCKI, and ROCKII
were gifts from G. Jones (both King’s College London,
London, UK). GFP-caldesmon and the deletion mutant
GFP-caldesmon-445 [35] were a gift from Alexander
Bershadsky (Weizman Institute of Science). The Ras-bind-
ing domain-glutathione S-transferase (RBD-GST) plasmid
was the gift of M. Schwartz (Yale University) [58]. GFP-
lifeact [32] was a gift from R. Wedlich-Soldner (MPI,
Munich, Germany).
The mRFP-fascin-1S39A and mRFP-fascin-1S39D con-
structs were prepared by subcloning cDNAs for human
fascin-1S39A and fascin-1S39D into pcDNA3-mRFP(N)
using the PCR primers shown in Table 1. mRFP-fascin-1
cDNA was generated from GFP-fascin-1WT by subclon-
ing into pCR-Blunt (Invitrogen Corp., Carlsbad, CA,
USA), using the PCR primers shown in Table 1, and then
subcloned into pcDNA3-mRFP(N) using HindIII and
EcoRI restriction sites. A vector encoding GFP-fascin-1
under control of a truncated CMV promoter (specGFP-
fascin-1) was generated by replacing the CMV promoter
by the speckled promoter from a GFP-paxillin plasmid
[59] (gift of R. Horwitz, University of Virginia) using AseI
and NheI restriction sites. GFP-LIMK1/2 mutant con-
structs were generated by site-directed mutagenesis using
the oligonucleotide pairs shown in Table 1.
For bacterial expression of 6His-tagged fascin-1, cDNAs
encoding wild-type, S39A, or S39D human fascin-1 from
the pEGFP-fascin-1 plasmids were cloned between the
NotI and XhoI restriction sites of pET-30a(+) (Novagen).
The reading frame was adjusted by subsequent digestion
and blunting of the NotI site. BIM, Y27632, ML7, BDM
and blebbistatin were obtained from Calbiochem (San
Diego, CA, USA). C3 endotoxin and RhoA G-LISA kit
were from Cytoskeleton Inc (). Antibodies used included
mouse monoclonal antibody to fascin-1 (clone 55k-2;
Dako, Glostrop, Denmark); to LIMK1, LIMK2 and phos-
phoLIMK1/2 (Cell Signaling Technology, Beverly, MA,
USA) and to Rho, ROCK I and II (BD Transduction Labs).
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Cell-extracellular matrix adhesion and
Immunofluorescence
C2C12 cells were maintained in DMEM containing 20%
fetal calf serum (FCS), and SW480 cells were maintained
in DMEM with 10% FCS. For transient transfections,
cells were plated at 30% to 40% confluency, and trans-
fected with transfection reagents (Polyfect (Qiagen Inc.,
Valencia, CA, USA or Lipofectamine 2000 (Invitrogen
Corp.)) in accordance with the manufacturer’s instruc-
tions. At 48 hours post-transfection, cells were re-plated
as single cell suspensions onto glass surfaces coated
with 50 nmol/L FN (Calbiochem) or Engelbreth-Holm-
Swarm (EHS) laminin (Sigma-Aldrich, St Louis, MO,
USA) under serum-free conditions, as described pre-
viously [5,18]. In experiments involving pharmacological
inhibitors, cells were pretreated with the agent for 30
minutes prior to the adhesion assays being set up, and
the agent was maintained in the medium throughout
the assay. The concentrations of inhibitors to be used
were established in pilot experiments, and the lowest
concentrations that affected cell morphology and actin
organization reproducibly without evidence of cytotoxi-
city, as determined by Trypan blue exclusion, were cho-
sen for the experiments. After 1 (C2C12) or 2 (SW480)
hours at 37°C to allow adhesion and initiation of ran-
dom cell migration, non-adherent cells were removed by
rinsing in Tris-buffered saline (TBS) and adherent cells
were fixed in 2% paraformaldehyde (EMS) and permea-
bilized in TBS with 0.5% Triton-X100 for staining with
tetramethyl rhodamine isothiocyanate-phalloidin
(Sigma), phalloidin-633, or antibodies to vinculin (clone
h-VIN1; Sigma) or phosphotyrosine (clone 4G10; Milli-
pore Corp., Billerica, MA, USA). For fascin-1 staining,
cells were fixed in absolute methanol, and for LIMK1/2
staining, they were fixed in 4% paraformaldehyde. Digi-
tal images were taken at room temperature under the
×63 objective of a laser scanning confocal microscope
using confocal acquisition software (Leica, Heerbrugg,
Switzerland). Morphometric analysis of adherent C2C12
cells was carried out by measuring cell areas and the
numbers and lengths of individual peripheral fascin or
F-actin bundles from calibrated digital images using the
software Improvision Openlab (Perkin Elmer, Waltham,
MA, USA).
Fluorescence resonance energy transfer/fluorescence
lifetime imaging microscopy
FLIM was performed cells transfected with specified
constructs, with fixation and data analyzed as described
previously [60]. Details of time-domain FLIM performed
with a multiphoton microscope system have been
described previously [60]. FLIM capability was provided
by time-correlated single-photon-counting electronics
(SPC 700; Becker & Hickl, Berlin, Germany). Widefield
acceptor (mRFP) images were acquired using a charge-
coupled device camera (Hamamatsu Photonics, Hama-
matsu, Japan) at exposure times of <100 ms. Data were
analyzed using TRI2 software (developed by Dr P. Bar-
ber). All histogram data were plotted as mean FRET
efficiency from >10 cells per sample. Lifetime images of
exemplary cells are presented using a pseudocolor scale,
with blue depicting normal GFP lifetime (that is, no
FRET) and red depicting reduced GFP lifetime (areas of
FRET). Each experiment was repeated at least three
times.
Live cell imaging
SW480 cells were transfected with GFP-fascin-1, and 24
hours later, were plated onto glass-bottomed imaging
chambers (LabTek; Nunc) coated with 15 nmol/l laminin
for 6 hours before treatment with DMSO (solvent con-
trol) or 10 μmol/l Y27632 for 30 minutes. Live confocal
microscopy imaging was performed on a microscope
(A1R; Nikon, Tokyo, Japan) equipped with a 40× oil
Table 1 Primer and oligonucleotide pairs used for PCR, cloning and site-directed mutagenesis
Name Direction Sequence
fascin-1S39A/D cDNAs Forward GTACGGATCCATGACCGCCAACGGCACAGCC
Subclonings into pcDNA3.mRFP(N) Reverse GTACGAATTCCTAGTACTCCCAGAGCGAGGC
fascin-1 cDNA Forward CCGGGAAGCTTCGCAGCGGCCTCTCG
Subcloning into pCR-Blunt Reverse GACGGGCCTAGGCTAGTACTCCCAGAG
LIMK1/460A mutagenesis Forward GAACATCATCCACCGAGCCCTCAACTCCCACAAC
Reverse GTTGTGGGAGTTGAGGGCTCGGTGGATGATGTTC
LIMK1/508A mutagenesis Forward GCAAGAAGCGCTACGCCGTGGTGGGCAAC
Reverse GTTGCCCACCACGGCGTAGCGCTTCTTGC
LIMK2/451A mutagenesis Forward GTGCATCATCCACCGGGCTCTGAACTCGCACAACTG
Reverse CAGTTGTGCGAGTTCAGAGCCCGGTGGATGATGCAC
LIMK2/505A mutagenesis Forward CGCAAGAAGCGCTACGCGGTGGTGGGAAACC
Reverse GGTTTCCCACCACCGCGTAGCGCTTCTTGCG
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objective lens (CFI Plan Fluor; Nikon) at 37°C. Images
were captured and exported with NIS Elements software
(Nikon). Movies were acquired as one image per 2 sec-
onds over 60 to 150 frames, and are presented at play-
back rates of 15 frames/second. Morphometric analyses
of filopodia formation in SW480 cells were performed by
measuring the number and length of GFP-tagged or RFP-
tagged fascin-positive filopodia, and by line-scan analysis
of fluorescence intensity along the length of single, ran-
domly selected filopodia. To analyze the dynamics of an
individual filopodium, kymographs of 2 × 10 μm areas
encompassing one filopodium were selected, and the
montage was performed in the X-axis. The mRFP-fascin-
1 signal was thresholded, the front of the filopodium out-
lined, and the resulting coordinates used to calculate sev-
eral dynamic values including maximum filopodia
displacement. All image analyses were performed with
ImageJ software (http://rsb.info.nih.gov/ij/download.
html). Each experimental condition was tested in at least
three independent experiments.
Immunoblotting and fascin-1 pull-downs
Adherent cells for immunoblotting were extracted on
ice in 1% Triton X-100 in TBS containing protease inhi-
bitor cocktail (Roche Diagnostics, Basel, Switzerland) for
12 minutes. SDS-PAGE and immunoblotting with
selected antibodies and enhanced chemiluminescence
(ECL) detection was carried out as described previously
[5]. Recombinant 6His-tagged fascin-1 was expressed in
BL21 E. coli by induction with 1 mmol/l isopropyl b-D-
1-hiogalactopyranoside (IPTG; Sigma-Aldrich) for 5
hours at 25°C. Bacterial pellets were resuspended in buf-
fer(300 mmol/l NaCl, 10 mmol/l imidazole and 50
mmol/l Na2HPO4 pH 8), then sonicated and clarified.
Lysates were passed over nickel-nitrilotriacetic acid (Ni-
NTA) beads (Qiagen Inc.) to allow fascin-1 binding,
beads were washed (300 mmol/l NaCl, 25 mmol/l imi-
dazole and 50 mmol/l Na2HPO4 pH 8), and fascin-1
was eluted (300 mmol/l NaCl, 250 mmol/l imidazole in
50 mmol/l Na2HPO4 (pH 8), and dialyzed against buffer
(150 mmol/l NaCl, 10 mmol/l imidazole and 50 mmol/l
Na2HPO4, pH 8). For pull-down experiments, the wild-
type or mutant fascin-1 proteins were immobilized on
Ni-NTA beads in disposable polystyrene chromatogra-
phy columns (Thermo Fisher Scientific Inc., Rockford,
IL, USA ). SW480 cell lysates were extracted (1% Triton,
150 mmol/l NaCl, 2 mmol/l MgCl2 and 10 mmol/l imi-
dazole pH 7.5), then passed through the columns,
washed extensively (1% Triton, 150 mmol/l NaCl, 2
mmol/l MgCl2 and 25 mmol/l imidazole, pH 7.5), and
the bound proteins were eluted (1% Triton, 150 mmol/l
NaCl, 2 mmol/l MgCl2 and 250 mmol/l imidazole pH
7.5). The eluted proteins were mixed with SDS-sample
buffer and subjected to SDS-PAGE and immunoblotting
as described previously [5].
Rho activity assays
Rho-GTP pull-down assays were carried out on extracts
from C2C12 cells adherent on 30 nmol/l FN for 1 hour
with a GST fusion protein containing the effector
domain of rhotekin (RBD-GST) as described previously
[58]. All extracts contained equivalent total Rho protein,
as measured by immunoblotting with anti-Rho (Trans-
duction Labs) and ECL detection. Rho-GTP levels were
compared with Rho status in C2C12 cells adherent on
30 mmol/l thrombospondin-1 for 1 hour or suspended
for 90 minutess over BSA-blocked dishes. RhoA-GTP
levels were also quantified with a G-LISA kit used in
accordance with manufacturer’s instructions (Cytoskele-
ton Inc). Lysates were prepared from SW480 cells plated
on 15 nmol/l laminin for 2 hours, either after 4 hours of
treatment with DMSO (control) or 1 μmol/l C3, or 30
minutes of pre-treatment with 1 μmol/l BIM.
Statistical analysis
Data were analyzed by descriptive statistics. P values
were calculated using a two-tailed Student’s t-test for
unpaired samples Triplicate samples were scored in
each experiment, and three to four independent experi-
ments were carried out for each experimental condition.
ANOVA was used to test statistical significance between
different populations of data. Statistical analysis was per-
formed with normalized data by one-way ANOVA and
subsequent multiple range test between conditions. P <
0.05 was considered significant.
Additional material
Additional file 1: Figure S1. (A) Demonstration that SW480 cells
migrating on laminin (LN) contain active Rho A, and that Rho is
effectively inhibited by C3 exotoxin under the experimental conditions.
(B,C) Co-localization of GFP-lifeact signal with phalloidin-633 signal and
mRFP-fascin-1 in areas of high fluorescence resonance energy transfer
(FRET) efficiency in SW480 cells on LN transiently expressing GFP-lifeact
and monomeric red fluorescent protein (mRFP)-fascin-1. Boxed area in
(B) is shown enlarged for each single-channel image and the lifetime
image in (C). Scale bars, (B) 10 μm; (C) 5 μm.
Additional file 2: Figure S2. (A) Immunoblots for expression of Rho
kinase isoforms, with 25 μg of cell extract was loaded per lane. Molecular
mass markers are in kDa. (B) Measurement of the interaction of
monomeric red fluorescent protein (mRFP)P-fascin-1S39A with GFP-lifeact
in C2C12 and SW480 cells, without or with Rho kinase inhibition. Cells
transiently transfected with the indicated plasmids were plated on
laminin (LN) for 2 hours, without or with pre-treatment with Y27632,
then fixed, mounted, and imaged using fluorescence lifetime imaging
microscopy (FLIM) to measure fluorescence resonance energy transfer
(FRET). In each panel, intensity multiphoton GFP (donor) images are
shown with the corresponding epifluorescence image for mRFP
(acceptor). Lifetime images are presented in a blue-to-red pseudocolor
scale with red as short lifetime. (C) Reduced filopodial localization of
fascin-1 upon inhibition of Rho kinases. Single -hannel images of
Jayo et al. BMC Biology 2012, 10:72
http://www.biomedcentral.com/1741-7007/10/72
Page 17 of 19
filopodia are shown from the same cells as presented in the merged
images in Figure 4D. Scale bars, 10 μm.
Additional file 3: Time-lapse confocal image avi movie 1. Monomeric
red fluorescent protein (mRFP)-lifeact dynamics in the same SW480 cell
before and after treatment with Y27632. Boxed 25 × 25 μm squares in
the lefthand panel are zoomed in on the righthand panel. Time-lapse
series were recorded every 2 seconds for 2 minutes, per cell and
treatment.
Additional file 4: Time-lapse confocal image avi movie 2. A
representative SW480 cell transiently expressing green fluorescent
protein (GFP)-fascin-1 and monomeric red fluorescent protein (mRFP)-
lifeact. Zoomed images represent the 25 × 25 μm box from the top-left
panel. Images were acquired every 2 sec over 4 minutes.
Additional file 5: Time-lapse confocal image avi movie 3. A
representative SW480 cell transiently expressing green fluorescent
protein (GFP)-fascin-1 and monomeric red fluorescent protein (mRFP)-
lifeact after treatment with Y27632. Zoomed images represent the 25 ×
25 μm box from the top-left panel. Images were acquired every 2 sec
over 4 minutes.
Additional file 6: Figure S3. (A) Co-localization of fascin-1 and LIMK1/2
in SW480 cells on laminin (LN). Confocal images of SW480 cell transiently
expressing low levels of green fluorescent protein (GFP)-fascin-1
(expressed under a truncated CMV promoter ‘SpecGFP’; see Methods),
were fixed and stained for endogenous p-Lin-11/Isl-1/Mec-3 kinase (LIMK)
1 (LH panel) or LIMK2 (RH panel). Arrows show examples of
concentrations of LIMK1 or LIMK2 that colocalized with fascin-1 at cell
peripheries. Scale bars, 10 μm. (B) Demonstration that LIMK1/2 activity
but not total LIMK1 protein is decreased in cells after treatment with Rho
inhibitor (C3 exotoxin) or Rho kinase inhibitor (Y27632). Molecular
markers are in kDa. Representative of three independent experiments. (C)
Representative single-channel images of localizations of GFP or GFP-
LIMK1 and mRFP-fascin-1 in SW480 cells on LN. Fascin-1 localizes along
the shafts of filopodia and GFP-LIMK1 localizes weakly towards the base
of filopodia. Right panels show zoomed single-channel and merged
images of the boxed 15 × 15 μm regions in the lefthand panels. Scale
bars, 10 μm. These images correspond to one timepoint of the merged
images in Figure 8A,B. (D) Representative confocal images of localizations
of GFP-LIMK1 and mRFP-lifeact in SW480 cells on LN. Scale bars, 10 μm.
Additional file 7: Time-lapse confocal image avi movie 4. A
representative SW480 cell expressing green fluorescent protein (GFP) and
monomeric red fluorescent protein (mRFP)-fascin-1. Zoomed images
represent the 15 × 15 μm square in the lefthand panel. Images were
acquired every 2 seconds over 2 minutes.
Additional file 8: Time-lapse confocal image avi movie 5. A
representative SW480 cell expressing green fluorescent protein (GFP)-
LIMK1 and monomeric red fluorescent protein (mRFP)-fascin-1. Zoomed
images represent the 15 × 15 μm square on the lefthand panel. Images
were acquired every 2 seconds over 2 minutes.
Additional file 9: Time-lapse confocal image avi movie 6. A
representative SW480 cell expressing green fluorescent protein (GFP)-
LIMK1-T508A and monomeric red fluorescent protein (mRFP)-fascin-1.
Zoomed images represent the 15 × 15 μm square on the lefthand panel.
Images were acquired every 2 seconds over 2 minutes.
Additional file 10: Time-lapse confocal image avi movie 7. A
representative SW480 cell expressing green fluorescent protein (GFP)-p-
Lin-11/Isl-1/Mec-3 kinase (LIMK)1-D460A and monomeric red fluorescent
protein (mRFP)-fascin-1. Zoomed images represent the 15 × 15 μm
square on the lefthand panel. Images were acquired every 2 seconds
over 2 minutes.
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